RecruitingNCT04743479
Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
Studying Familial pancreatic carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Changhai Hospital
- Principal Investigator
- Gang Jin, M.D.Department of general surgery, Changhai Hospital
- Intervention
- high-resolution MRI/CT examinations(diagnostic_test)
- Enrollment
- 5000 target
- Eligibility
- 50-75 years · All sexes
- Timeline
- 2020 – 2030
Study locations (1)
- Shanghai Changhai Hospital, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04743479 on ClinicalTrials.govOther trials for Familial pancreatic carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07344220Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye ConjugateHoag Memorial Hospital Presbyterian
- ENROLLING BY INVITATIONNANCT06744595Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic CancerMayo Clinic
- ACTIVE NOT RECRUITINGNCT04247503Cohort Study of Pancreatic Cancer RiskMayo Clinic
- ACTIVE NOT RECRUITINGNCT03060720Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized TherapyDana-Farber Cancer Institute
- RECRUITINGNCT01102569Pancreatic Cancer GeneticsColumbia University
- ACTIVE NOT RECRUITINGNCT00835133Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and MelanomaMayo Clinic